238120 — Aligned Genetics Income Statement
0.000.00%
Last trade - 00:00
- KR₩64bn
- KR₩54bn
- KR₩15bn
- 35
- 32
- 76
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,794 | 7,957 | 11,762 | 13,753 | 15,215 |
Cost of Revenue | |||||
Gross Profit | 4,612 | 4,543 | 7,347 | 8,766 | 10,670 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 8,193 | 8,211 | 9,583 | 10,904 | 11,878 |
Operating Profit | -399 | -253 | 2,179 | 2,849 | 3,337 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 117 | 468 | 3,813 | 2,442 | 3,424 |
Provision for Income Taxes | |||||
Net Income After Taxes | 117 | 468 | 5,542 | 2,333 | 3,236 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 117 | 468 | 5,542 | 2,333 | 3,236 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 117 | 468 | 5,542 | 2,333 | 3,236 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.8 | 32.6 | 385 | 162 | 227 |
Dividends per Share |